Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17087362rdf:typepubmed:Citationlld:pubmed
pubmed-article:17087362lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0085504lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C2003888lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0023779lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0577631lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0449258lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:17087362lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:17087362pubmed:issue8lld:pubmed
pubmed-article:17087362pubmed:dateCreated2006-11-7lld:pubmed
pubmed-article:17087362pubmed:abstractTextRecent experimental and epidemiological findings suggest that infectious agents may play a role in the development and progression of atherosclerosis. We previously reported that Chlamydia pneumoniae (C. pneumoniae) infection reduces the effectiveness of lipid-lowering therapy for carotid atherosclerosis and that this micro-organism may play a role in the progression of atherosclerosis. In this study, we investigated the possible association between hepatitis C virus (HCV) infection and carotid arteriosclerosis. A total of 165 asymptomatic hypercholesterolemic patients were randomized to receive probucol (500 mg/day, n=82) or pravastatin (10 mg/day, n=83) and were followed for 2 years. The 2-year change of the maximum common carotid artery intima-media thickness (Max-IMT) was the primary endpoint, while the Max-IMT and the incidence of major cardiovascular events were secondary endpoint. All serum samples were tested for antibody to HCV (anti-HCV) by enzyme-linked immunosorbent assay (ELISA), and all anti-HCV-positive samples were assayed for HCV RNA. Patients without HCV infection (n=25) showed a significant reduction of Max-IMT (-10.9%) (p<0.0001), while a small decrease of Max-IMT was noted in the patients with HCV infection (n=25) (-0. 3%). Significant differences in the reduction of serum total cholesterol and LDL cholesterol were found between patients with and without HCV infection (both p<0.0001). No significant difference in therapeutic effect was noted between the probucol and the pravastatin groups. After adjustment for confounding risk factors, both C. pneumoniae infection and anti-HCV positivity were associated with a greater risk of an increase in Max-IMT (8.5635 [1.3738-15.7532], p<0.05, 9.5040 [0.2886-18.7194], p<0.05, respectively). These findings suggest that both chronic HCV infection and C. pneumoniae infection can reduce the effectiveness of lipid-lowering therapy for carotid atherosclerosis, and that the HCV may play a role in the progression of atherosclerosis in HCV infected patients.lld:pubmed
pubmed-article:17087362pubmed:languageenglld:pubmed
pubmed-article:17087362pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17087362pubmed:citationSubsetIMlld:pubmed
pubmed-article:17087362pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17087362pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17087362pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17087362pubmed:statusMEDLINElld:pubmed
pubmed-article:17087362pubmed:monthAuglld:pubmed
pubmed-article:17087362pubmed:issn0016-254Xlld:pubmed
pubmed-article:17087362pubmed:authorpubmed-author:SawayamaYasun...lld:pubmed
pubmed-article:17087362pubmed:authorpubmed-author:HayashiJunJlld:pubmed
pubmed-article:17087362pubmed:authorpubmed-author:FurusyoNorihi...lld:pubmed
pubmed-article:17087362pubmed:authorpubmed-author:MaedaShinjiSlld:pubmed
pubmed-article:17087362pubmed:authorpubmed-author:OkadaKyokoKlld:pubmed
pubmed-article:17087362pubmed:authorpubmed-author:OhnishiHachir...lld:pubmed
pubmed-article:17087362pubmed:issnTypePrintlld:pubmed
pubmed-article:17087362pubmed:volume97lld:pubmed
pubmed-article:17087362pubmed:ownerNLMlld:pubmed
pubmed-article:17087362pubmed:authorsCompleteYlld:pubmed
pubmed-article:17087362pubmed:pagination245-55lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:meshHeadingpubmed-meshheading:17087362...lld:pubmed
pubmed-article:17087362pubmed:year2006lld:pubmed
pubmed-article:17087362pubmed:articleTitleBoth hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy.lld:pubmed
pubmed-article:17087362pubmed:affiliationDepartment of General Medicine, Kyushu University Hospital.lld:pubmed
pubmed-article:17087362pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17087362pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:17087362pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17087362lld:pubmed